Journal of Pharmacology and Experimental

Zhang, Y. and Wells, J., The effects of chronic caffeine administration on peripheral adenosine receptors, Journal of Pharmacology and Experimental Therapeutics, 254, 757, 1990. [Pg.252]

Rush, C., Sullivan, J. and Griffiths, R., Intravenous caffeine in stimulant drug abusers Subjective reports and physiological effects. Journal of Pharmacology and Experimental Therapeutics 273(1), 351-358, 1995. [Pg.295]

Lauver DA, Lockwood SF, and Lucchesi BR. 2005. Disodium disuccinate astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. Journal of Pharmacology and Experimental Therapeutics 314(2) 686-692. [Pg.56]

Zeng, H., Lozinskaya, I.M., Lin, Z., Willette, R.N., Brooks, D.P. and Xu, X. (2006) Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. The Journal of Pharmacology and Experimental Therapeutics, 319, 957-962. [Pg.78]

Nau, C., Seaver, M., Wang, S.Y. and Wang, G.K. (2000) Block of human heart hHl sodium channels by amitriptyline. The Journal of Pharmacology and Experimental Therapeutics, 292. 1015-1023. [Pg.82]

Anantharam, A., Markowitz, S.M. and Abbott, G.W. (2003) Pharmacogenetic considerations in diseases of cardiac ion channels. The Journal of Pharmacology and Experimental Therapeutics, 307, 831-838. [Pg.83]

Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H. and Wrighton, S.A. (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. The Journal of Pharmacology and Experimental Therapeutics, 301, 427—434. [Pg.124]

H, X.Q., Bjorkman, A., Andersson, T.B., Ridderstrom, M. and Masimirembwa, C.M. (2002) Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2 C8 a new high affinity and turnover enzyme-specific probe substrate. Journal of Pharmacology and Experimental Therapeutics, 300 (2), 399-407. [Pg.233]

Thummel, K.E., Shen, D.D., Podoll,T.D., Kunze, K.L., Trager, W.F., Bacchi, C.E., Marsh, C.L., McVicar, J.P., Barr, D.M., Perkins, J.D., Carithers, R.L. (1994) Use of midazolam as a human cytochrome P450 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271 (1), 557-566. [Pg.236]

Sutton, D., Butler, A.M., Nadin, L. and Murray, M. (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282 (1), 294-300. [Pg.236]

Ernest, C.S., II, Hall, S.D. and Jones, D. R. (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapeutics, 312 (2), 583-591. [Pg.244]

C. M. Jr. (1972) Physiological disposition of fenprofen in man. III. Metabolism and protein binding of phenprofen. Journal of Pharmacology and Experimental Therapeutics, 183, 449. [Pg.291]

Sitar, D.S. and Thornhill, D.P. (1973) Methimazole absorption, metabolism and excretion in the albino rat. Journal of Pharmacology and Experimental Therapeutics, 184, 432. [Pg.291]

Egnell, A.-C., Houston, B. and Boyer, S. (2003) in vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. The Journal of Pharmacology and Experimental Therapeutics, 305, 1251-1262. [Pg.333]

Gao, B., Hagenbuch, B., Kullak-Ublick, G.A., Benke, D., Aguzzi, A. and Meier, P. J. (2000) Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics, 294, 73-79. [Pg.356]

Lau, Y.Y., Okochi, H., Huang, Y. and Benet, L.Z. (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites application of in vitro and ex situ systems. Journal of Pharmacology and Experimental Therapeutics, 316, 762-771. [Pg.357]

Zhang, Y., Schuetz, J.D., Elmquist, W.F. and Miller, D.W. (2004) Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. Journal of Pharmacology and Experimental Therapeutics, 311, 449-455. [Pg.359]

Chu, X.Y., Suzuki, H Ueda, K., Kato, Y Akiyama, S. and Sugiyama, Y. (1999) Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. Journal of Pharmacology and Experimental Therapeutics, 288, 735-741. [Pg.359]

Nozawa, T., Imai, K., Nezu, J., Tsuji, A. and Tamai, I. (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. Journal of Pharmacology and Experimental Therapeutics, 308,438—445. [Pg.366]

P. L., McCloskey, T. C., Johnson, M.P., McCarty, D. R., Poirot, M., Senyah, Y., Siegel, B. W Widmaier, C. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. The Journal of Pharmacology and Experimental Therapeutics, 277, 968—981. [Pg.508]

Gunasekar PG, Sun PW, Kanthasamy AG, etal. 1996. Cyanide-induced neurotoxcity involves nitric oxide and reactive oxygen species generation after N-Methyl-D-aspartate receptor activation. The Journal of Pharmacology and Experimental Therapeutics 277 150-155. [Pg.252]

Journal of Pharmacology and Experimental Therapeutics Figure 11. Changes in mean arterial pressure ( S.E.) in conscious rabbits after 500 fig of 1-propanolol ICV and i.o. (35)... [Pg.22]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...